151 related articles for article (PubMed ID: 1363288)
1. Disruption of synaptosomal calcium channel function by Lambert-Eaton myasthenic immunoglobulin is serum-dependent.
Hewett SJ; Atchison WD
Brain Res; 1992 Dec; 599(2):317-23. PubMed ID: 1363288
[TBL] [Abstract][Full Text] [Related]
2. Specificity of Lambert-Eaton myasthenic syndrome immunoglobulin for nerve terminal calcium channels.
Hewett SJ; Atchison WD
Brain Res; 1992 Dec; 599(2):324-32. PubMed ID: 1363289
[TBL] [Abstract][Full Text] [Related]
3. Serum and plasma from patients with Lambert-Eaton Myasthenic Syndrome reduce depolarization-dependent uptake of 45Ca2+ into rat cortical synaptosomes.
Hewett SJ; Atchison WD
Brain Res; 1991 Dec; 566(1-2):320-4. PubMed ID: 1814548
[TBL] [Abstract][Full Text] [Related]
4. Binding of Lambert-Eaton myasthenic syndrome IgG to synaptosomal proteins does not correlate with an inhibition of calcium uptake.
Martin-Moutot N; Lang B; Newsom-Davis J; Seagar M
Neurosci Lett; 1995 Mar; 187(2):115-8. PubMed ID: 7783957
[TBL] [Abstract][Full Text] [Related]
5. The proteins synaptotagmin and syntaxin are not general targets of Lambert-Eaton myasthenic syndrome autoantibody.
Hajela RK; Atchison WD
J Neurochem; 1995 Mar; 64(3):1245-51. PubMed ID: 7861157
[TBL] [Abstract][Full Text] [Related]
6. Passive transfer of Lambert-Eaton myasthenic syndrome induces dihydropyridine sensitivity of ICa in mouse motor nerve terminals.
Xu YF; Hewett SJ; Atchison WD
J Neurophysiol; 1998 Sep; 80(3):1056-69. PubMed ID: 9744921
[TBL] [Abstract][Full Text] [Related]
7. Selective action of myasthenic syndrome antibodies on calcium channels in a rodent neuroblastoma x glioma cell line.
Peers C; Lang B; Newsom-Davis J; Wray DW
J Physiol; 1990 Feb; 421():293-308. PubMed ID: 2161458
[TBL] [Abstract][Full Text] [Related]
8. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.
Shimizu F; Takeshita Y; Sano Y; Hamamoto Y; Shiraishi H; Sato T; Yoshimura S; Maeda T; Fujikawa S; Nishihara H; Kitanosono H; Tsujino A; Motomura M; Kanda T
Brain; 2019 Aug; 142(8):2253-2264. PubMed ID: 31236596
[TBL] [Abstract][Full Text] [Related]
9. Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.
Flink MT; Atchison WD
J Bioenerg Biomembr; 2003 Dec; 35(6):697-718. PubMed ID: 15000529
[TBL] [Abstract][Full Text] [Related]
10. Lambert-Eaton syndrome IgG inhibits transmitter release via P/Q Ca2+ channels.
Spillane J; Ermolyuk Y; Cano-Jaimez M; Lang B; Vincent A; Volynski KE; Kullmann DM
Neurology; 2015 Feb; 84(6):575-9. PubMed ID: 25589670
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of non-L-, non-N-type (Q-like) Ca2+ channels by Lambert-Eaton myasthenic syndrome (LEMS) antibodies in rat insulinoma RINm5F cells.
Magnelli V; Grassi C; Parlatore E; Sher E; Carbone E
FEBS Lett; 1996 May; 387(1):47-52. PubMed ID: 8654565
[TBL] [Abstract][Full Text] [Related]
12. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction.
Peers C; Johnston I; Lang B; Wray D
Neurosci Lett; 1993 Apr; 153(1):45-8. PubMed ID: 8390031
[TBL] [Abstract][Full Text] [Related]
13. Lambert-Eaton myasthenic syndrome: immunoglobulin G inhibition of Ca2+ flux in tumor cells correlates with disease severity.
Lang B; Vincent A; Murray NM; Newsom-Davis J
Ann Neurol; 1989 Mar; 25(3):265-71. PubMed ID: 2543262
[TBL] [Abstract][Full Text] [Related]
14. [Molecular immunology of voltage-gated calcium channel and Lambert-Eaton myasthenic syndrome].
Iwasa K; Komai K; Yasukawa Y; Maruta T; Takamori M
Nihon Rinsho; 1997 Dec; 55(12):3322-30. PubMed ID: 9436458
[TBL] [Abstract][Full Text] [Related]
15. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder.
Vincent A; Lang B; Newsom-Davis J
Trends Neurosci; 1989 Dec; 12(12):496-502. PubMed ID: 2480664
[TBL] [Abstract][Full Text] [Related]
16. Lambert-Eaton syndrome antibodies inhibit acetylcholine release and P/Q-type Ca2+ channels in electric ray nerve endings.
Satoh Y; Hirashima N; Tokumaru H; Takahashi MP; Kang J; Viglione MP; Kim YI; Kirino Y
J Physiol; 1998 Apr; 508 ( Pt 2)(Pt 2):427-38. PubMed ID: 9508807
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.
Lang B; Pinto A; Giovannini F; Newsom-Davis J; Vincent A
Ann N Y Acad Sci; 2003 Sep; 998():187-95. PubMed ID: 14592874
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of calcium channel autoantibodies detected using a small-cell lung cancer line derived from a Lambert-Eaton myasthenic syndrome patient.
Johnston I; Lang B; Leys K; Newsom-Davis J
Neurology; 1994 Feb; 44(2):334-8. PubMed ID: 8309586
[TBL] [Abstract][Full Text] [Related]
19. Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission.
Flink MT; Atchison WD
J Physiol; 2002 Sep; 543(Pt 2):567-76. PubMed ID: 12205190
[TBL] [Abstract][Full Text] [Related]
20. The synaptic vesicle protein synaptotagmin associates with calcium channels and is a putative Lambert-Eaton myasthenic syndrome antigen.
Leveque C; Hoshino T; David P; Shoji-Kasai Y; Leys K; Omori A; Lang B; el Far O; Sato K; Martin-Moutot N
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3625-9. PubMed ID: 1314395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
